I
31.83
-0.90 (-2.74%)
| Previous Close | 32.72 |
| Open | 32.30 |
| Volume | 325,740 |
| Avg. Volume (3M) | 2,411,588 |
| Market Cap | 3,978,902,528 |
| Price / Earnings (TTM) | 32.47 |
| Price / Earnings (Forward) | 10.44 |
| Price / Sales | 3.21 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -5.30% |
| Operating Margin (TTM) | 25.56% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -6.30% |
| Quarterly Earnings Growth (YOY) | -23.00% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 135.00 M |
| Levered Free Cash Flow (TTM) | 264.88 M |
| Return on Assets (TTM) | 12.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Indivior Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | 0.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.02% |
| % Held by Institutions | 89.09% |
| 52 Weeks Range | ||
| Median | 48.00 (50.83%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Jan 2026 | 48.00 (50.82%) | Buy | 34.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KINGSLEY STUART A | 32.27 | - | 940 | 30,334 |
| RYAN BARBARA | 31.86 | - | 39 | 1,259 |
| Aggregate Net Quantity | 979 | |||
| Aggregate Net Value ($) | 31,593 | |||
| Aggregate Avg. Buy ($) | 31.99 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RYAN BARBARA | Director | 13 Mar 2026 | Buy (+) | 8 | 31.11 | 249 |
| RYAN BARBARA | Director | 09 Mar 2026 | Buy (+) | 31 | 32.60 | 1,011 |
| KINGSLEY STUART A | Director | 06 Mar 2026 | Buy (+) | 940 | 32.27 | 30,334 |
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ |
| 26 Jan 2026 | Announcement | Indivior Announces Completion of Redomiciliation to the United States |
| 08 Jan 2026 | Announcement | Indivior Provides Full-Year 2026 Financial Guidance and Business Update |
| 22 Dec 2025 | Announcement | Indivior Announces Inclusion in the S&P SmallCap 600® Index |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |